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Abstract
Background: Otitis media with effusion (OME) is an accumulation of fluid in the middle ear affecting about 80 %
of children by the age of 4 years. While OME usually resolves spontaneously, it can affect speech, behaviour and
development. Children with persistent hearing loss associated with OME are usually offered hearing aids or
insertion of ventilation tubes through the tympanic membrane. Oral steroids may be a safe and effective treatment for
OME, which could be delivered in primary care. Treatment with oral steroids has the potential to benefit large numbers
of children and reduce the burden of care on them and on health services. However, previous trials have either been
too small with too short a follow-up period, or of too poor quality to give a definite answer.
The aim of the Oral Steroids for the Resolution of Otitis Media with Effusion in Children (OSTRICH) trial is to determine
if a short course of oral steroids improves the hearing of children with OME in the short and longer term.
Methods/design: A total of 380 participants (children of 2 to 8 years of age) are recruited from Hospital Ear, Nose and
Throat departments in Wales and England. A trained clinician seeks informed consent from parents of children with
symptoms for at least 3 months that are attributable to OME and with confirmed bilateral hearing loss at study entry.
Participants are randomised to a course of oral steroid or a matched placebo for 1 week. Outcomes include
audiometry, tympanometry and otoscopy assessments; symptoms; adverse effects; functional health status;
quality of life; resource use; and cost effectiveness. Participants are followed up at 5 weeks, and at 6 and 12 months
after the day of randomisation. The primary outcome is audiometry-confirmed satisfactory hearing at 5 weeks.
Discussion: An important evidence gap exists regarding the clinical and cost effectiveness of short courses of
oral steroid treatment for OME. Identifying an effective, safe, nonsurgical intervention for OME in children for
use in primary care would be of great benefit to children, their families and the NHS.
Trial registration: ISRCTN: ISRCTN49798431 (Registered 7 December 2012)
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Background
Otitis media with effusion (OME) is the most common
cause of hearing loss in children in the United Kingdom,
and up to 80 % of children are affected by OME by
4 years of age [1]. Overall, the prognosis for OME is
good, with more than 50 % of OME episodes resolving
spontaneously within 3 months and 95 % within 1 year.
However, 30 to 40 % of children have recurrent OME
episodes, and 5 % of preschool children (under 5 years
of age) have persistent (longer than 3 months) bilateral
hearing loss associated with OME [2].
Hearing loss from OME can have an important im-
pact on children’s mood, communication, concentra-
tion, learning, socialisation and language development.
This may affect other family members and family func-
tion. OME in early childhood can affect IQ, behaviour
and reading into teenage years [3].
The UK National Institute of Clinical Excellence (NICE)
guideline (2008) for OME management recommends a
‘watchful waiting’ period of 3 months, with referral to
an Ear, Nose and Throat (ENT) department if hearing
is significantly affected, OME persists for longer than
3 months, or if there is suspected language or develop-
mental delay [4]. Treatment options for these children
are limited to hearing aids or surgical insertion of ven-
tilation tubes (grommets) through the tympanic mem-
brane. Hearing aids are an effective treatment, but this
intervention is not problem-free; children often find
them uncomfortable, may feel self-conscious and may
become a target for bullying [5].
Although the diagnosis of OME in primary care has
increased over the last decade, the number of grommet
operations performed in England fell from 43,300 in
1994 to 1995 to 25,442 in 2009 to 2010, primarily as a
result of the ‘watchful waiting’ strategy [6]. However,
OME remains the most common reason for childhood
surgery in the UK and comprises a considerable work-
load for hospital ENT departments. Furthermore, a wide
variation exists in the rate of grommet surgery among
regions, which is unlikely to be explained by variation in
the disease. In Wales, a six-fold variation exists in the
European age-standardised rates of grommet surgery be-
tween the highest and the lowest local authorities [7].
Both hearing aids and surgery require referral to sec-
ondary care, with major cost consequences. The Depart-
ment of Health commissioned ‘McKinsey’ report states
that the National Health Service (NHS) could save £21
million per year by reducing grommet insertion by a fur-
ther 90 %, a procedure that they assessed as being ‘rela-
tively ineffective’ [8]. This position has been challenged.
Deafness Research UK and the 2009 ENT UK Position
Paper conclude that reducing access to grommets will
disadvantage thousands of children who have a genuine
need of treatment [9, 10].
Antibiotics, topical intranasal steroids, decongestants,
antihistamines and mucolytics are all ineffective treat-
ments for OME [11–13]. A rigorous evaluation of anti-
inflammatory treatment for OME has been a priority for
many years [14]. Cochrane systematic reviews have
found insufficient evidence for the effectiveness of both
oral steroids and autoinflation (AI) devices in resolving
OME in children to recommend implementation but
sufficient evidence to recommend further research [12].
A recent trial of an AI device in children with OME
and 4 to 11 years of age found a modest effect for some
children [15]. However, 80 % of children are affected by
OME before the age of 4 years at the time when lan-
guage development is most rapid, and hearing loss has
its greatest effect on language development [3]. There-
fore, alternatives to hearing aids or surgery for children
less than 4 years of age (who are unable to use an AI de-
vice) are required.
Williamson et al. (2009) evaluated topical intranasal
steroids for children with OME in general practice and
found they are unlikely to be clinically effective for OME
[16].
Topical steroids applied through the nose would not
be expected to reach the middle ear. However, systemic
steroids do reach the middle ear epithelium and modu-
late OME in animal models [17].
The evidence from in vitro and animal models sug-
gests that steroids reduce effusions and middle ear pres-
sure [18–21]. Various mechanisms have been proposed
for a role for steroids in resolving middle ear effusions,
including (a) reducing arachidonic acid and associated
inflammatory mediators, (b) shrinking peri-eustachian
tube lymphoid tissue, (c) enhancing secretion of eusta-
chian tube surfactant with a resultant improvement in
tubal function, and (d) reducing middle ear fluid viscos-
ity by its action on mucoproteins [22].
The latest update of the Cochrane review on oral or
topical steroids for OME (last search August 2010)
found no benefit from intranasal steroids [12]. However,
the review did identify evidence of a statistically signifi-
cant benefit from oral steroids plus antibiotics versus an-
tibiotics alone for OME (5 studies, 409 participants,
23 % in the intervention group and 47 % in the control
group with persistent OME at follow-up), and a trend
towards a significant benefit for oral steroids versus pla-
cebo in the short term (3 studies, 108 participants). Oral
antibiotics alone are not effective. The only study to as-
sess the effect of oral steroids on hearing as an outcome
was underpowered.
Studies included in the systematic review were short-
term, underpowered, often poorly described inclusion
criteria and/or did not assess hearing at the time of in-
clusion, used ears rather than children as the unit of
analysis, and used intermediate outcome measures, such
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as tympanometry results, rather than improved hearing.
No cost effectiveness studies of oral steroids for OME
were found. Therefore, insufficient evidence exists to
recommend oral steroids as a treatment for persistent
OME because of inadequate evidence about short-term
effect on hearing and cost-effectiveness, and absence of
evidence about longer-term effects.
No significant adverse effects of steroids were reported
by the studies included in the Cochrane review. How-
ever, the number of participants was too small to rule
out that possibility. Short courses of prednisolone are
widely used in treating children with acute asthma, and
adverse events are extremely rare; when they do occur,
they are largely limited to behavioural disturbances and
dyspepsia and resolve on withdrawal of the steroid drug.
The safety of multiple short courses of oral steroid ther-
apy has been evaluated [23]. Short courses of oral ste-
roids such as prednisolone do not have lasting negative
effects on bone metabolism, bone density, adrenal gland
function or weight or height, even if used on several oc-
casions over the course of a year [24].
An important evidence gap exists regarding the clin-
ical and cost effectiveness of short courses of oral steroid
treatment for OME. Identifying an effective, safe, cost-
effective, acceptable non-surgical intervention for OME
in children (including those in the first 4 years of life)
for use in primary care remains an important research
priority.
The OSTRICH trial aims to determine the clinical
and cost effectiveness of a 7-day course of oral prednis-
olone (steroid) on improving hearing over the short
term in children with bilateral OME, as diagnosed at an
ENT outpatient or Paediatric Audiology/Audiovestibular
Medicine (AVM) clinic, who have had symptoms attribut-
able to OME present for at least 3 months and current
significant hearing loss (demonstrated by audiometry).
Methods/design
Objectives
The primary objective of the OSTRICH trial is to deter-
mine the clinical and cost effectiveness of a 7-day course
of oral steroid on improving hearing at 5 weeks from
randomisation in children with bilateral OME, who have
had symptoms attributable to OME present for at least
3 months and have current significant hearing loss
(demonstrated by audiometry). Oral steroids are likely to
have their effect within the first few weeks, and most of
the existing evidence is for an effect at 4 to 6 weeks.
This is, therefore, the time point at which the maximum
effect is expected.
Design
OSTRICH is a double-blind, individually randomised,
placebo-controlled trial involving children with persistent
OME and significant hearing loss. It will randomise 380
children (2 to 8 years of age) to receive a 1-week course of
oral prednisolone or a matching placebo. All participants
are followed up at 5 weeks, 6 months and 12 months after
the day of randomisation.
Setting
This trial is implemented in secondary care sites across
Wales and England. Participants are identified in ENT
outpatient or Paediatric Audiology and Audiovestibular
Medicine (AVM) clinics.
Participants
Children 2 to 8 years old with symptoms of hearing loss
for at least 3 months attributed to OME are eligible to
join the trial if they meet the following inclusion criteria.
Inclusion criteria
The inclusion criteria are as follows:
1. Age 2 to 8 years (for example, has reached the 2nd
birthday and has not yet reached the 9th birthday).
2. Symptoms of hearing loss attributable to OME for
at least 3 months (or had audiometry proven
hearing loss for at least 3 months).
3. Diagnosis of bilateral OME made in an ENT or
Paediatric Audiology and AVM clinic on the day
of recruitment or during the preceding week.
4. Audiometry confirming hearing loss of more than
20 dBHL averaged within the frequencies of 0.5, 1,
2, and 4 KHz in both ears by pure tone audiometry
(PTA) ear-specific insert, visual reinforcement
audiometry (VRA) or ear specific play audiometry,
or hearing loss of more than 25 dBHL averaged
within the frequencies of 0.5, 1, 2, and 4 KHz by
sound-field VRA or sound-field performance/play
audiometry in the better hearing ear, on the day of
recruitment or within the preceding 14 days.
5. First time in the OSTRICH trial.
6. Parent/carer able to understand and give informed
consent.
Exclusion criteria
Children with one of more of the following are not eli-
gible for inclusion:
1. Current involvement in another clinical trial of
an investigational medicinal product (CTIMP)
or have participated in a CTIMP during the last
4 months.
2. Current systemic infection or ear infection.
3. Cleft palate, Down’s syndrome, diabetes mellitus,
Kartagener’s or primary ciliary dyskinesia, renal
failure, hypertension or congestive heart failure.
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4. Confirmed, major developmental difficulties
(for example, are tube fed or have chromosomal
abnormalities).
5. Existing known sensory hearing loss.
6. Taken oral steroids in the preceding 4 weeks.
7. Had a live vaccine in the preceding 4 weeks if
under 3 years of age.
8. Has a condition that increases their risk of adverse
effects from oral steroids (that is, on treatment,
the immune system is likely to be modified, or are
immunocompromised, such as undergoing cancer
treatment).
9. Has been in close contact with someone known
or suspected to have Varicella (chicken pox) or
active Zoster (shingles) during the 3 weeks prior to
recruitment and have no prior history of Varicella
infection or immunisation.
10.Already has grommets (ventilation tubes).
11.On a waiting list for grommet surgery and anticipate
having surgery within 5 weeks and are unwilling to
delay it.
Trial intervention
Participants randomised to the active treatment arm re-
ceive a 7-day course of oral soluble Prednisolone, as a
single daily dose of 20 mg for children 2 to 5 years of
age or 30 mg for 6- to 8-year olds. The daily dose stated
is the most commonly used dose in previous studies of
OME and is similar to the standard dose for the treat-
ment of other conditions with inflammatory components
(such as asthma). Piramal Healthcare UK Limited has a
Medicines and Healthcare Products Regulatory Agency
(MHRA) Manufacturing Authorisation and has repack-
aged and supplied the soluble Prednisolone tablets.
Control arm
Participants randomised to the control arm receive a
7-day course of oral placebo. This is matched for
consistency, colour and solubility, as well as visually, in
identical packaging to the active treatment. The placebo is
manufactured, packaged and supplied by Piramal Health-
care UK Limited.
The trial medication is prescribed by the patient’s clin-
ician and dispensed by the site Pharmacy.
Outcomes
The primary outcome is acceptable hearing at 5 weeks
from randomisation (4 weeks after conclusion of treat-
ment), where acceptable hearing is defined as ‘less
than or equal to 20 decibel hearing level (dBHL)’ aver-
aged within the frequencies of 0.5, 1, 2 and 4 kilohertz
(kHz) in at least one ear in children assessed by pure
tone audiometry (PTA), ear-specific insert visual
reinforcement audiometry (VRA) or ear-specific play
audiometry, and ‘less than or equal to 25 dBHL’ aver-
aged within the frequencies of 0.5, 1, 2 and 4 KHz in
children assessed by sound-field VRA or sound-field
performance/play audiometry. These thresholds are
based on national guidelines [25].
Secondary outcomes
The secondary outcomes assess the longer term (up to
12 months) effects of the intervention on the following:
1. Acceptable hearing at 6 and 12 months
(defined as above).
2. Tympanometry (using calibrated standardised
tympanometers and modified Jerger classification
Types A, B and C).
3. Otoscopic findings.
4. Healthcare consultations related to OME and
other resource use.
5. Grommet surgery at 6 and 12 months.
6. Adverse effects.
7. Symptoms (reported by parent and child if
appropriate).
8. Functional health status.
9. Health-related quality of life.
10. Short and longer term cost effectiveness.
Trial procedures
Site selection and training
Trial sites are selected on the basis of their recruitment
potential and being part of a well-established clinical re-
search network. All sites receive training in trial-specific
procedures and good clinical practice (GCP). The train-
ing materials are designed specifically to train different
staff groups, depending on their roles and responsibil-
ities. For example, the Principal Investigator (PI) and
designated trial clinicians are trained on trial-specific
tasks including assessing eligibility, taking informed con-
sent and prescribing. OSTRICH nurses (term used in
this protocol to refer to clinic nurse, research nurse or
clinical studies research officer) are trained in registration,
data collection, and handling of the trial medication. Phar-
macy staff members are trained in Investigational Medicinal
Product (IMP) management procedures, such as storing, al-
locating and dispensing, as well as temperature monitoring
and reconciliation for each randomised patient.
Designated staff members are responsible for cascad-
ing training and delegating specific Protocol tasks to
other trial site staff.
Participant recruitment
The recruitment process is summarised in Fig. 1.
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Registration and consent
Participating clinicians (ENT or Audiovestibular Medi-
cine) identify eligible patients with bilateral hearing loss
and diagnosis of OME during routine outpatient consul-
tations, from current grommet surgery waiting lists or
from hearing aid review lists. Additionally, potentially
eligible children are identified in Audiology, Audioves-
tibular (AVM), Paediatric Audiology and Community
Audiology clinics, and interested parents/legal guardians
will be directed to the participating OSTRICH clinician.
Each child has an audiometry assessment and a clinical
assessment (both routine procedures for those attending
these clinics) before they are assessed for eligibility to
enter the trial. The participating clinician further as-
sesses eligibility, provides the potential participant’s par-
ent/legal guardian with a verbal description of the trial
and, if they are interested, provides a comprehensive
Participant Information Sheet (PIS). All potential partici-
pants’ parents/legal guardians are given sufficient time
to read the PIS, ask questions and consider participation
before being asked to provide written informed consent
if they are willing for their child to participate. Age-
appropriate pictorial information sheets are also be pro-
vided for children who are old enough to use them.
Parents/legal guardians who consent to take part are
asked to sign a consent form, which is also signed by the
clinician who is taking consent. Parents/legal guardians
are informed that they have the right to withdraw consent
from participation in the OSTRICH trial at any time, and
that the clinical care of their child is not affected at any
time by declining to participate or withdrawing from the
trial. Assent may be given by children who are able to
understand the age-appropriate information provided and
express an opinion regarding their participation.
Fig. 1 Trial schema and participant flow diagram
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All participating sites are asked to keep an anonymous
screening log of all ineligible and eligible but not con-
sented/not approached patients. These are used to meas-
ure potential selection bias.
Randomisation and blinding
Randomisation
Randomisation is coordinated centrally by the South
East Wales Trials Unit (SEWTU). The randomisation
schedule prepared by the Trial Statistician (TS) com-
prises random permuted blocks that are stratified by
site and child’s age. The IMP Manufacturer (Piramal
Healthcare UK Limited) was provided with a list of ran-
dom allocation numbers linking to either the steroid or
placebo. Whether the allocations relate to the steroid
or placebo was determined by an independent statisti-
cian to ensure the TS remains blinded. The allocation
numbers are used to label the trial medication packs.
Each trial medication pack has a unique identification
number (Trial Pack number).
As children are recruited, they are assigned the next
vacant Participant Identification number (PID). Trial
medication packs are only released once informed con-
sent has been obtained and a consent form signed. Par-
ticipants are randomised to receive either the steroid or
the matching placebo by receiving the next sequentially
numbered Trial Pack allocated to the participant by the
site Pharmacy. A designated member of the OSTRICH
trial site team (where possible) or the participant’s par-
ent/legal guardian collects the pack from Pharmacy on
behalf of the participant. Participant randomisation is
considered to have occurred once a consent form is
signed and the Trial Pack opened. The Trial Pack num-
ber is then entered onto the participant’s case report
form (CRF).
Blinding
Participants, parent/legal guardians, clinic staff and mem-
bers of the OSTRICH trial team remain blind to treatment
allocation. The unique identification number on each Trial
Pack is linked to the randomisation schedule. If clini-
cians at sites are providing clinical treatment for a ser-
ious adverse event (SAE), they contact SEWTU if
unblinding is required.
Data collection
Baseline/clinical assessments
An eligibility case report form (CRF) is completed for all
consented participants to ensure that they meet the eli-
gibility criteria specified in the trial protocol. The clin-
ician signs the form to confirm that the participant is
eligible to be enrolled into the trial.
A participant registration form is completed by the
OSTRICH nurse to register the participant and their
parent/legal guardian to the trial (this includes collecting
names and addresses of the participants and their par-
ent/legal guardians).
The OSTRICH nurse and clinician complete the CRFs,
recording medical history and audiometry, tympanome-
try and otoscopy measurements. Table 1 provides an ex-
planation of the clinical assessments of this trial.
In current practice, the recommended standard methods
to assess hearing thresholds are ear-specific pure tone
audiometry (PTA) at 0.5, 1, 2 and 4 kHz in children 3 years
or older, and sound-field visual reinforcement audiometry
(VRA) in children under 3. However, equally, those chil-
dren under 3 years of age may comply with PTA. There-
fore, we recommend that the audiologist/clinician use
their judgement on the most appropriate method of as-
sessment for the child and, where possible, maintain that
method for subsequent follow-ups.
We are aware that ear-specific VRA through the use
of insert earphones is considered ‘gold standard’ practice
but believe that sound-field VRA will provide a reason-
able assessment of the child’s level of hearing and will
ensure the feasibility and wider applicability of the trial
in a range of research sites due to wider availability.
Functional health status and quality of life
The parent/legal guardian is asked to complete a ques-
tionnaire booklet comprising the Otitis Media (OM8-
30) questionnaire to assess the child’s Functional
Health Status [26], the Paediatric Quality of Life Inven-
tory (PedsQL) to measure health-related quality of life
[27], and the Health Utilities Index Mark 3 (HUI 3) to
measure health utilities [28]. If appropriate, a child’s
version of the questionnaire booklet is also completed
by the participant, comprising the child self-report ver-
sion of PedsQL.
Diary
The OSTRICH nurse provides parents/legal guardians
with a symptom diary to take home and complete over
Table 1 Clinical measurements
Measurement Outcome
Audiometry Hearing in each ear by pure tone
audiometry, ear-specific insert visual
reinforcement audiometry (VRA) or
ear-specific play audiometry) or in both
ears together by sound-field VRA or
sound-field performance/play
audiometry)
Tympanometry (using
calibrated standardised
tympanometers and modified
Jerger classification Type B and
C considered abnormal)
Presence of middle ear effusion
in each ear
Otoscopy Appearance of tympanic membrane
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the first 5 weeks. In the first week, this is completed
daily to record treatment adherence. Thereafter, it is
completed weekly for 4 weeks to record symptoms, ad-
verse events, healthcare resource usage (which includes
general practitioner (GP) and practice nurse consulta-
tions, procedures, investigations, hospital appointments,
accident and emergency (A&E) attendances and any
hospital inpatient admissions), additional medication
taken, time off school/nursery and parental time off
work.
The OSTRICH nurse provides the parent/legal guardian
with the trial medication (where possible) or the prescrip-
tion for the parent/legal guardian to take to the Pharmacy
themselves, and discusses taking the trial medication if ap-
propriately qualified to do so. A medication guidance and
instructions for use leaflet is also provided to parent/legal
guardian. The next clinic appointment (at week 5) is made
for the participant to attend, and the parent/legal guardian
is advised that there are further follow-up clinic visits at 6
and 12 months.
Follow-up assessments
Follow-up assessments for all participants are conducted
at week 5 (4 weeks post completion of treatment, + 2-
week window), 6 and 12 months (±2-week window).
At the 5-week follow-up appointment, any unused trial
medication is collected and returned to the Pharmacy
for disposal, and the OSTRICH nurse collects the com-
pleted symptom diary from the parent/legal guardian.
Completion of the questionnaire booklets and the clin-
ical assessments (for example, audiometry, tympanome-
try, and otoscopy) are repeated at each of the follow-up
clinic appointments. Although the follow-up of partici-
pants is continued for 12 months, after the 5 week as-
sessment all participants resume ‘usual care’, and all
treatment decisions are made by their parents in con-
sultation with their clinician.
The questionnaire booklets at 6 and 12 months also
include healthcare resource usage to assess use of NHS
resources, additional medication taken, time off school/
nursery and parental time off work.
In the event that participants’ follow-up appointments
are missed at the proposed time points, SEWTU coord-
inate with the trial site staff, and the parent/legal guard-
ian of the participant is contacted by telephone to
rearrange the visit as soon as possible. In the event that
telephone contact is not successful, visit reminder letters
are sent to rearrange the appointment.
If parents/legal guardians are unable or unwilling to
attend a follow-up appointment, they are asked if they
are willing to complete the questionnaire booklet that
would be sent to them in the post. A freepost self-
addressed envelope is provided for parents to return
their diary, unused medication and/or questionnaire
booklet. Alternatively, they will be given the option of
answering a brief questionnaire over the telephone,
comprising questions extracted from the diary regard-
ing symptoms (for the 5-week follow-up, if not com-
pleting/returning the diary) and quality of life (if not
completing and returning a questionnaire booklet).
Analysis
Sample size
The sample size calculation is based on demonstrating a
change in the rate of resolution of hearing loss at 5 weeks
post randomisation (4 weeks post completion of treat-
ment) from 20 % in the control group to 35 % in the
intervention group. OME resolves spontaneously in a
high proportion of children, and some studies have
found a significantly higher rate of spontaneous reso-
lution. For example, Williamson et al. found a resolution
rate in their control group of 47 % [16]. However, we an-
ticipate a lower spontaneous rate of resolution because
we will only include children who have been symptom-
atic for at least 3 months and are recruiting children in a
secondary care setting, where a more severe spectrum of
illness can be anticipated. The Cochrane review of ste-
roids for OME reported a ratio of proportions for reso-
lution of OME at 2 weeks of 3.80 (95 % CI = 0.93 to
15.52). In the five studies in the Cochrane review of oral
steroids versus placebo, overall there was a 23 % recov-
ery rate in the placebo plus antibiotic group and a 47 %
recovery rate in the oral steroid plus antibiotic group,
which represents a 24 % difference (antibiotics on their
own are ineffective) [12]. We have selected a conserva-
tive estimate of 1.75 for our effect size (ratio of propor-
tions) because we believe that a 15 % absolute increase
in the rate of resolution at 5 weeks would represent a
clinically meaningful benefit that could result in a mean-
ingful reduction in unnecessary operations and a related
saving in cost for the NHS. In order to demonstrate a
difference between 20 % and 35 % with an alpha of 0.05
and 80 % power, we will need 302 participants (nQuery
software version 4.0). We will recruit 380 to allow for a
20 % loss to follow-up at 1 year. Although our primary
outcome data will be gathered at 5 weeks, we believe
that it is important to be able to assess long-term out-
comes and, therefore, want to ensure that we will have
sufficient power for longer term follow-up assessments.
Statistical analysis
The primary analyses will be intention to treat and will
employ a logistic regression model to investigate differ-
ences in the proportion of children with acceptable
hearing at the 5 weeks post randomisation follow-up
appointment between the two treatment arms, adjust-
ing for site. Comparisons will be presented as the
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absolute difference in proportions and the adjusted
odds ratio, with 95 % confidence interval and P value.
Secondary outcomes with a binary outcome (present/
absent), such as satisfactory hearing and presence of ef-
fusion, will employ repeated measures logistic regression
to investigate differences between the trial arms and over
time (5 weeks and 6-month and 12-month follow-ups).
Changes in hearing over time will also be analysed to
identify children who show early resolution but then re-
lapse. For continuous secondary outcomes, such as
PedsQL, and OM8-30 scores, repeated measures linear
regression models (using transformations as necessary)
will be used to investigate differences between the trial
arms and over time (5 weeks, 6 months and 12 months)
adjusting for baseline. The duration between the start
and the resolution of the symptoms will be calculated
and the median (interquartile range) for each rando-
mised group will be presented. A Cox regression model
will be used to test whether time to resolution differs be-
tween the randomised groups.
A number of outcomes will be calculated from the
parents’ diary for the first 5 weeks, such as total time off
school/nursery and work (days) and the number of
healthcare consultations. These will be analysed using
Poisson regression to investigate differences between the
two trial arms.
Previous researchers have mapped OM8-30 scores to
utility values on the HUI-3 scale. As this trial measures
both OM8-30 and HUI-3, it provides the opportunity to
evaluate the generalisability of the existing mapping.
This will be done by correlating the mapped utility
values on the HUI-3 scale (obtained via the mapping for-
mula from the OM8-30 facet scores) with the newly ac-
quired HUI-3 scores.
Possible confounders such as the child’s age and his-
tory of atopy and relevant interaction terms will be
entered into the primary regression analyses for each
of the outcomes in order to conduct pre-specified sub-
group analyses. These subgroups will be defined in
advance of any analysis based on the best available evi-
dence. Since the trial is powered to detect overall dif-
ferences between the groups rather than interactions
of this kind, the results of these exploratory analyses
will be presented using confidence intervals as well as
P values. No interim analyses are planned.
Full description of the methods to be used will be
stated in a trial statistical analysis plan.
Economic analysis/cost effectiveness analysis
The cost-effectiveness analysis will be conducted from
the perspective of the UK NHS and Personal Social Ser-
vices and also will consider a broader partial societal
perspective, encompassing impacts on patients and their
families. The cost-effectiveness component will have two
time durations: a within-trial assessment and a longer
term time horizon based on decision-analytic modelling
and populated from parameter estimates derived from
the trial and from information from literature sources
relating to long-term effects of hearing difficulties in
children. These time periods offer a longer duration than
previous studies and will be used, alongside other
sources, to arrive at more meaningful estimates of cost-
effectiveness.
The costs of the course of oral steroids will be calcu-
lated and combined with differences in costs between
intervention and control groups to determine overall
costs associated with the intervention. The resource util-
isation of both groups (consultations, medications, oper-
ations, equipment, etcetera) and treatments associated
with adverse events, will be assessed through the com-
pletion of self-completed questionnaires at baseline, at
5 weeks, 6 months and 12 months and translated into
costs using appropriate published unit costs [29].
The difference in overall costs between groups will be
compared with differences in outcomes, as specified
above, and including quality-adjusted life years (QALYs).
QALYs will be computed from PedsQL and HUI 3 and
from utilities derived from mapping responses to the
OM8-30 questionnaire [30].
A series of one-way sensitivity analyses will be con-
ducted to assess the impact of parameter variation on
baseline estimates of the cost-effectiveness ratios and a
probabilistic sensitivity analysis undertaken to determine
the extent to which the intervention can be regarded as
representing value for money.
Ethical and governance approval
This trial protocol was reviewed and approved by
Wales Research Ethics Committee (REC) 3, which is
recognised by the United Kingdom Ethics Committee
Authority (UKECA). All hospital sites received Re-
search and Development approval from the respective
NHS Health Boards and Trusts in Wales and England.
These were Cardiff and Vale University Health Board,
Aneurin Bevan University Health Board, Cwm Taf
Health Board, Abertawe Bro Morgannwg University
Health Board, Hywel Dda University Health Board,
Betsi Cadwaladr University Health Board, The Royal
Wolverhampton NHS Trust, The Newcastle Upon Tyne
NHS Foundation Trust, Bradford Teaching Hospitals
NHS Foundation Trust, London North West Healthcare
NHS Trust, Maidstone and Tunbridge Wells NHS Trust,
Royal Free London NHS Foundation Trust, University
College London Hospitals NHS Foundation Trust,
University Hospitals of North Midlands NHS Trust,
Isle of Wight NHS Trust, Sheffield Children’s NHS
Foundation Trust, Central Manchester University
Hospitals NHS Foundation Trust, Brighton and Sussex
Waldron et al. Trials  (2016) 17:115 Page 8 of 10
University Hospitals NHS Trust, Surrey and Sussex
Healthcare NHS Trust, Blackpool Teaching Hospitals
NHS Foundation Trust, Walsall Healthcare NHS Trust
and Worcestershire Acute Hospitals NHS Trust. Clinical
Trial Authorisation was obtained from the Medicines and
Healthcare products Regulatory Agency (MHRA).
Discussion
OSTRICH will be the first adequately powered trial to
evaluate the clinical and cost-effectiveness of a short
course of oral steroids for the resolution of OME in
children in the short term and longer term. Some clini-
cians already prescribe oral steroids for OME with
others opposed to such practice. The analysis proposed
by OSTRICH will generate much needed evidence that
will greater inform clinicians and will dispel the
strongly opposing views about the use of oral steroids
for the treatment of OME.
If shown to be effective, the use of oral steroids for
OME could benefit children and provide the option of
primary care treatment as opposed to costly secondary
care.
The economic analysis will assess the cost of any bene-
fits achieved through the use of oral steroids for the
resolution of OME in children. In addition to direct
costs, this will include any savings (or additional costs)
that result from prescribing the oral steroid. For ex-
ample, costs for the NHS may be lowered if the number
of grommet operations that are needed is reduced. This
will provide additional important information to health-
care providers and funders to aid them in making the
most efficient use of their finite resources.
Conversely, if shown not to be clinically effective, then
that information will provide evidence to change prac-
tice where they are currently being used, and research
efforts could focus on developing alternative pathways
for improving the management of OME in children.
The OSTRICH trial will address the important evi-
dence gap regarding clinical and cost effectiveness of
short courses of oral steroid treatment for OME. Identi-
fying an effective, safe, cost-effective, acceptable non-
surgical intervention for OME in children (including
those in the first 4 years of life) for use in primary care
remains an important research priority and would be of
great benefit to children, their families and the NHS.
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